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The human brain is a vast and complicated network, where billions of nerve cells use 
signals to communicate with each other. Signals must be rapid and precise. Within a 
neuron, this speed is achieved using electrical signals that are conducted along extended, 
cable-like processes. At chemical synapses, these electrical signals are first converted into 
chemical signals by the release of neurotransmitter into a narrow synaptic gap after 
depolarization of the presynaptic cell. Neurotransmitter-gated ion channels at the 
postsynaptic cell, which act as complete signal-transduction systems, reconvert signals 
from chemical to electrical in under one millisecond. After the transmitter is released and 
binds to an extracellular region of the receptor, the channel opens to excite or inhibit the 
train of postsynaptic action potentials. Just as important, the channel closes within a few 
milliseconds as the transmitter dissociates to terminate the synaptic event. Chemical 
synaptic transmission offers the advantages of signal amplification, reversal of signal 
polarity and greater potential for modulation, all important properties for higher brain 
function.  
Pentameric neurotransmitter-gated ion channels (LGICs) play key roles in chemical 
synapses throughout the nervous system, and include receptors activated by acetylcholine 
(ACh), γ-aminobutyric acid, glycine and serotonin (5-HT) (LeNovere and Changeux, 2001; 
Lester et al., 2004). They are known as the Cys-loop receptors because all family subunits 
contain in their amino-terminal, extracellular halves, a pair of disulfide-bonded cysteines, 
which are separated by 13 residues. Their vital role in converting chemical recognition into 
an electrical impulse makes these receptors prime loci for learning, memory and disease 
processes, as well as targets for clinically relevant drugs. Over the past 30 years, LGICs 
have been the major targets of the most commonly prescribed drugs, such as 
neuromuscular blockers, barbiturates and benzodiazepines. In the last years an ever 
increasing number of human and animal diseases have been found to be caused by 
defective ion channel function of Cys-loop receptors.  
In vertebrates, the Cys-loop superfamily consists of two families of cation-selective 
channels: the nicotinic (AChR) and the 5-hydroxytryptamine type 3 receptors (5HT3); and 
two families of anionic channels, the γ-aminobutyric acid receptor (GABAA and GABAC) 
and the glycine (GlyR) receptors. The repertoire of invertebrate LGIC is larger, including a 
GABA-gated cation channel (Beg and Jorgensen, 2003), serotonin- and ACh-gated anion 
channels (Putrenko et al., 2004 JBC), and histamine-gated channels (Zheng et al., 2002). 
The selectivity of the channels for cations or anions governs the sign of the current, and in 
turn, the type of response: inhibitory, for anionic channels because they hyperpolarize the 
cell, and excitatory, for cationic channels because they induce membrane depolarization 
by allowing a net influx of Na+ ions into the cell.  
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The AChRs have received arguably the most attention of all members of the family. 
They have been object of attention since Claude Bernard investigated the action of the 
Central American arrow poison, curare. The muscle AChR was the first to be identified 
and purified, and the first to be characterized biochemically and electrophysiologically.  
The AChR is widely distributed throughout the animal kingdom, from nematodes to 
human (Le Novere and Changeux, 1995). They are expressed in many regions of the 
central and peripheral nervous system. In muscle, AChR plays a major role in 
neuromuscular transmission, initiating the action potential which ends in muscle 
contraction. This receptor is the target of competitive blockers, such as curare, and other 
muscle relaxants used in surgery. In nematodes, muscle AChRs are targets for 
anthelmintic chemotherapy (Jones and Satelle, 2003). In neuronal tissues, AChRs 
contribute to a wide range of brain activities and influence a number of physiological 
functions (Gotti and Clementi, 2004). ACh is probably the oldest signaling molecule, and 
appeared very early in evolution before nervous system. It is present in bacteria, algae, 
protozoa and plants, and AChRs are also present in various non-neuronal tissues, such 
as blood cells (De Rosa et al., 2005), keratinocytes, lung cells (Gotti and Clementi, 2004).  
The 5HT3 receptor is found in the central and peripheral nervous system. It is known 
to be involved in sensory processing, nociception, emesis, cardiovascular regulation, gut 
function (Hoyer et al., 2002; Yang et al., 2003). Selective antagonists are used as 
antiemetic agents during antineoplasic therapy. 
The GABAA and GlyR receptors are involved in the inhibition in the central nervous 
system, with the GABAA distributed throughout the CNS and the GlyR found predominantly 
in the brainstem and spinal cord. The activity of GABA receptors is allostercially enhanced 
by benzodiazepines, barbiturates, intravenous anesthetics, alcohols, steroids and volatile 
anesthetics; and it is blocked by picrotoxin. GlyR are targets of the plant alkaloid 
strychnine, which by acting as competitive antagonists leads to agitation, muscle spasms, 
and convulsions. Therefore, developing therapeutic agents against GlyR may have 
significant utility as muscle relaxants and analgesic agents (Connolly and Wafford, 2004). 
 
 
OVERALL STRUCTURE 
Cys-loop receptors are composed of five identical (homopentamers) or different 
(heteropentamers) polypeptide chains arranged around an axis perpendicular to the 
membrane (Fig. 1). The analysis of the evolutionary relationships within the superfamily 
suggests that the ancestor receptor was probably homo-oligomeric and appeared 2500 
million years ago (Ortells and Lunt, 1995; LeNovere and Changeux, 1995). Homomeric 
receptors are the structurally simplest type of Cys-loop receptor. They diverged least from 
the common ancestral Cys-loop receptor and likely share functional features found among 
all members of the superfamily. Subunits are classified as α or non-α, with the α subunits 
containing a CC motif in the binding site. A wide number of α and non-α subunits have 
been cloned for all members of the superfamily (Ligand-gated ion channel database, 
http://www.ebi.ac.uk/compneur-srv/LGICdb/cys-loop.php).  
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Fig. 1. Schematic arrangement of the adult muscle AChR. The pentameric receptor is composed 
of two α and three different non-α subunits  (β, ε and δ).  Each subunit contains a large extracellular domain 
and four transmembrane segments. This transmembrane disposition in conserved in all Cys-loop receptors. 
 
The subunits of this gene superfamily are built on a modular basis. The extracellular 
domain forms the agonist binding sites. The transmembrane domain contains the pore 
and the channel gate, the structure that prevents ion flow in the absence of agonist and 
swings open to allow flow in its presence (Lester et al., 2004). 
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The extracellular domain: location of the agonist binding sites 
Our knowledge of the structure of the extracellular domain of the Cys-loop receptors 
took a giant step forward with the solution of the high-resolution structure of the 
acetylcholine binding protein (AChBP) from Lymnaea stagnalis (Brejc et al., 2001). This 
soluble protein is produced and stored in glial cells and is released in an ACh-dependent 
manner in the synaptic cleft where it regulates synaptic transmission. AChBP lacks the 
transmembrane region and contains many of the structural cornerstones that give AChRs 
their unique signature and has therefore become a functional and structural surrogate of 
the extracellular domain of the Cys-loop receptors (Review in Sine, 2002). It contains 210 
amino acids and is 15-24% identical to aligned sequences of the amino-terminal, 
extracellular halves of AChR, 5HT3 and GABA subunits.   Each AChBP monomer consists 
of an N-terminal α-helix, two short 310 helices, and a core of 10 β-strands that form a 
sandwich. The N- and C- termini are located at top and bottom of the pentamer, 
respectively. In the Cys-loop receptors, the end of β10 connects to the start of M1. Located 
at the bottom of the subunit, the linker between β6 and β7 is the signature Cys-loop found 
in all members of the superfamily. The binding sites are located at the interfaces between 
subunits, at about 40 Å above the membrane. One subunit, the α subunit, contributes 
three loops that span beta strands and harbor key aromatic residues, while the adjacent 
subunit, called the complementary subunit, contributes three beta strands that harbor 
aromatic and hydrophobic residues, and a fourth loop that harbors negatively charged 
residues. AChBP has been used to create homology-based models of the extracellular 
domains of 5-HT3, AChR and GABAA (Cromer et al., 2002; Reeves et al., 2003; Niesler 
al., 2003).  
 
The transmembrane domain: the region that comprises the ion pore and the gate 
The transmembrane half of each Cys-loop receptor subunit is composed of 4 
transmembrane segments (M1-M4) (Fig. 1). Structural and electrophysiological studies 
have shown that the ion channel is largely lined by the M2 domains of the five subunits. 
Using cryo-electron microscopy to a resolution of 4 Å a model of the closed pore of 
Torpedo AChR has been recently reported (Miyazawa et al., 2003; Fig. 2). The model 
shows that the pore is shaped by an inner ring of 5 α-helices (M2 segments) and an outer 
ring of 15 α-helices, which coil around each other and shield the inner ring from the lipids 
(Fig. 2). The pore is maximally constricted in the middle of the membrane due to side-to-
side interactions between hydrophobic residues of neighboring helices. This tight 
hydrophobic girdle creates an energetic barrier to ions across the membrane, and thus it 
has been suggested that it corresponds to the gate (Miyazawa et al., 2003). During gating, 
twisting of the M2 helices may disrupt the girdle and, in turn, allows ion flux.  
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Fig. 2. Molecular model of the closed (resting) AChR pore of Torpedo californica (modified from 
Miyazawa et al., 2003). The coordinates were taken from the Protein Data Bank with accession code 10ED 
(Miyazawa et al., 2003). The models were drawn with ViewerPro 4.2 (Accelrys Inc.). 
 
The ion pore contains the filter selectivity, which is the structure that determines 
which type of ions may pass through the channel. Point mutations in the M2 region 
supported the role of positions –2 to 2´ as main determinants of the selectivity filter of all 
Cys-loop receptors (Review in Barry and Lynch, 2005).   
The long intracellular loop between M3 and M4 contains phosphorylation sites and is 
thought to be associated with cytoskeletal proteins, such as rapsyin for AChR, gephyrin for 
GlyR, and GABARAP and MAP1B for GABAA and GABAC, respectively (Passafaro and 
Sheng, 1999). These proteins allow the clustering of the receptors at appropriate regions 
of the membrane. In addition, this loop has been shown to contribute to channel kinetics in 
muscle AChRs (Bouzat et al., 1994; Wang et al., 2000). 
 
The interface between extracellular and transmembrane domains: a region involved 
in coupling agonist binding to channel gating 
The junction between binding and pore domains has recently emerged as crucial for 
coupling binding to gating (Bouzat et al., 2004; Kash et al., 2003; Chakrapani et al., 2004). 
To identify the structural requirements for functionally coupling extracellular and 
transmembrane domains, we generated a chimeric receptor composed of the AChBP 
protein, which presumably evolved without the constraint of functional coupling to an ion 
pore, and the pore domain from the 5HT3 receptor (Bouzat et al., 2004). Only when amino-
acid sequences of three loops (β1-β2, Cys and β8-β9 loops) in AChBP were changed to 
α 
β 
ε 
δ 
α 
M1 
M4 
M3 
M2 
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their 5HT3 counterparts does ACh bind with low affinity characteristic of activatable 
receptors and trigger opening of the ion pore. Thus, the functional coupling process is 
mediated by a network of loops from both domains, including three from the binding 
domain and one from the pore domain (M2-M3 linker). This region mediates a bi-
directional allosteric interaction between the binding sites and the pore domain. Structural 
modeling shows that the Cys-loop and β1-β2 linker straddle opposite sides of the M2-M3 
linker from the pore domain (Fig. 3), suggesting a twisting motion during coupling that in 
turn twists the pore-lining M2 domain to allow flow of cations (Bouzat et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Homology model of the chimeric AChBP-5HT3A receptor with key regions of one subunit 
color-coded. These loops, which are located at the interface between binding and pore domains, are 
involved in the coupling of agonist binding to channel gating. From Bouzat et al. (2004). 
 
The complete atomic-resolution structure of any fast synaptic receptor channel has 
not been resolved yet. However, a refined model of the membrane-associated Torpedo 
AChR in the closed state obtained from electron images at 4 Å resolution has been 
recently presented (Unwin, 2005). The high level of amino acid sequence  conservation 
imply that all channels of the Cys-loop superfamily are constructed around the same three-
dimensional framework and function according to the same global principles (Unwin, 
2005).  
 
 
FROM STRUCTURE TO FUNCTION 
Cys-loop receptors are allosteric proteins: they are oligomeric, contain multiple 
agonist-binding sites, non-competitive antagonist sites, and gates that interact at a 
distance through changes in the quaternary structure of the receptor. They also open and 
desensitized, albeit with less probability, in the absence of agonist.  Receptors can be 
Cys-loop 
M2-M3 
β8-β9 
β1-β2 
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therefore found in different conformational states: closed or resting, which is more stable in 
the absence of agonist; open, which is transient and stabilized by the presence of agonist; 
and desensitized, which predominates after a prolonged exposure to agonist. In addition, 
intermediate conformational states between open or closed and desensitized states may 
exist in the AChR (Spitzmaul et al., 2001; Ryan et al., 2001).  
The combination of site-directed mutagenesis and cell expression with single-
channel recordings using the patch-clamp technique (Hamill et al., 1981) had a clear 
impact in the field by disclosing relationships between molecular structure and functional 
properties for all members of the superfamily. The AChR is the best electrophysiologically 
characterized receptor. Emerging from the early biophysical studies of the receptor 
function, the following core mechanism was established and still serves today as a starting 
point for quantitatively describing muscle AChR activation: 
 
                       AR*         
                  β1          α1 
              k+1                     k+2                 β2                           
A + R             AR  + A                A2R              A2R*           (Scheme 1) 
                          k
-1                       k-2                   α2                             
 
where two agonists (A) bind to the receptor (R) in the resting state with association 
rates k+1 and k+2, and dissociate with rates k-1 and k-2. Receptors occupied by one agonist 
open with rate β1 and close with rate α1, and AChRs occupied by two agonist molecules 
open with rate β2 and close with rate α2.  Further insight into the process of activation has 
been provided by kinetic analysis of single channels (Cheng et al., 1995; Ohno et al., 
1995; Sine et al., 1995; Qin et al., 1996; Wang et al., 2000; Grosman et al., 2000a,b; 
Bouzat et al., 2000, 2002; Shelley and  Colquhoun, 2005). Mutations may produce 
changes in channel function by affecting one or more of the rate constants in Scheme 1. 
Kinetic analysis allows the evaluation of the changes in the rate constant(s), thus providing 
insights into the relationship between structure and channel gating. This approach has 
been extensively used to associate a specific residue or domain with a kinetic step of the 
activation process.  
 
FROM FUNCTION TO PATHOLOGY 
During the last decade, an ever increasing number of channelopathies have been 
described. These diseases result from defects in ion channel function. The identification of 
the molecular mechanisms leading to the disease is necessary for rational therapy.  
Neuronal AChRs are involved in a wide variety of diseases affecting the nervous 
system and non-neuronal tissues, such as Tourette syndrome, attention-deficit hyperactive 
disorder, schizophrenia, autosomal dominant nocturnal frontal lobe epilepsy, febrile 
convulsions, depression and anxiety, Alzheimer´s and Parkinson´s disease (Lena and 
Changeux, 1998; Gotti and Clementi, 2004).  
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Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the 
safety margin of neuromuscular transmission is compromised by one or more presynaptic, 
synaptic, or postsynaptic mechanisms. The majority of CMS are caused by mutations in 
the AChR subunits. Some of them lead to kinetic abnormalities which may cause a loss 
(fast channel syndrome) or a gain of function (slow channel syndrome) (Engel et al., 
2003). The slow-channel CMS are dominant mutations that increase activation of the 
receptor by speeding the rate of opening of the channel, slowing the rate of closing of the 
channel, or allowing repeated opening during each ACh occupancy. The first study of a 
CMS revealing how a kinetic abnormality may cause a disease was reported by the groups 
of Sine and Engel at Mayo Clinic (Ohno et al., 1995). Molecular genetic analysis of a 
patient suffering from a congenital myasthenic syndrome demonstrated a substitution of 
proline for threonine at the M2 domain of the muscle ε subunit. Genetically engineered 
mutant AChRs expressed in HEK cells revealed that the mutation leads to markedly 
prolonged openings in the presence of agonist and increase openings even in the absence 
of ACh (Ohno et al., 1995, Fig. 4). The result is a staircase summation of endplate 
potential that cause depolarization block of the muscle action potential. In addition, cationic 
overloading of the postsynaptic region caused by the cholinergic overactivity results in an 
endplate myopathy due to destruction of junctional folds. Since then, kinetic analysis of 
spontaneous mutations in human AChR subunits that cause CMS highlighted functionally 
significant residues or domain. Mutations causing increase-of-function phenotypes have 
been shown to occur in the extracellular region, in the M2-M3 linker, and in the 
transmembrane domains of different subunits (for reviews see Engel et al., 1998, 2002, 
2003). Knowledge of the pathological alterations occurring in CMS at the molecular level 
has important consequences for future therapeutic strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 M2 Epsilon 
Xenopus C T V S I S V L L A Q T V F L F L I A 
Mouse A 
Rat A 
Bovine 
C T V S I N V L L A Q T V F L F L I 
C T V S I N V L L A Q T V F L F L I 
C T V S I N V L L A Q T V F L F L I A 
Human C T V S I N V L L A Q T V F L   F L I A 
Patient P 
264 
Control 
Patient 
Wild-type 
Mutant εT264P 
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Fig. 4. Slow-channel congenital myasthenic syndromes: The mutation εT264P increases the 
open duration of the muscle AChR. (Upper panel) Aligned amino acid sequences of the M2 domain of the 
ε subunit. In the patient, the highly conserved T264 is replaced by a proline. (Lower panel) Comparison of 
channel events recorded from normal human endplate (control) and a CMS endplate (patient) and from HEK 
cells expressing wild-type (wild-type) and mutant εT264P (mutant) AChR channels. Markedly prolonged 
channel events at CMS EP and in HEK cells expressing the εT264P mutation are observed. ACh 
concentration: 1 µM. Taken from Ohno et al. (1995). 
 
Interestingly, mutations at equivalent regions of different Cys-loop receptors have 
been shown to lead to diseases, thus confirming a common fundamental mechanism of 
channel gating. Inherited mutations located in the M2-M3 domain of the GlyR α1-subunit 
are associated with human startle disease (hyperekplexia) (Shiang et al. 1993) and Startle 
syndromes in other species (Rajendra and Schofield, 1995). The effect of these mutations 
is to disrupt signal transduction (Rajendra et al., 1995). An inherited mutation in the M2-M3 
loop is associated with a congenital myasthenic syndrome in the muscle AChR (Grosman 
et al., 2000b), and with a rare form of epilepsy in the GABAA receptor (Baulac et al., 2001).  
 
 
CONCLUDING REMARKS 
There is still much to learn. Ligand binding and channel gating are dynamic 
processes that require precise and coordinated movements of the protein, which have 
recently begun to be unraveled. Desensitization still remains a complex and mysterious 
process.  
If the goal of designing new ligands targeted to specific LGICs subtypes or to 
mutated receptors at the origin of the disease states is to be fulfilled, we require an 
intimate knowledge of the structure-function relationship of them. There is hope that the 
new understanding of the molecular pharmacology of Cys-loop receptors will led to a new 
generation of more selective drugs with improved safety profiles.  
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